Last $141.54 USD
Change Today +0.83 / 0.59%
Volume 1.4M
AMGN On Other Exchanges
Symbol
Exchange
Hong Kong
Mexico
Sao Paulo
As of 3:30 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

amgen inc (AMGN) Snapshot

Open
$140.90
Previous Close
$140.71
Day High
$141.88
Day Low
$139.95
52 Week High
09/18/14 - $141.87
52 Week Low
10/9/13 - $105.76
Market Cap
107.6B
Average Volume 10 Days
2.9M
EPS TTM
$6.69
Shares Outstanding
759.6M
EX-Date
08/12/14
P/E TM
21.2x
Dividend
$2.44
Dividend Yield
1.63%
Current Stock Chart for AMGEN INC (AMGN)

amgen inc (AMGN) Details

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

20,000 Employees
Last Reported Date: 02/24/14
Founded in 1980

amgen inc (AMGN) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.5M
Executive Vice President of Operations
Total Annual Compensation: $1.1M
Executive Vice President of Global Commercial...
Total Annual Compensation: $1.0M
Executive Vice President of Research & Develo...
Total Annual Compensation: $896.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $845.9K
Compensation as of Fiscal Year 2013.

amgen inc (AMGN) Key Developments

Amgen Announces Results from Several New Exploratory Analyses Evaluating Long-Term Impact of Treatment with Prolia(R) (Denosumab) in Postmenopausal Women with Osteoporosis

Amgen announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia(R) (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic T-scores (>-2.5) at the lumbar spine and total hip from baseline. Additional Prolia data of interest are detailed below. Prolia is the first approved therapy that specifically targets RANK Ligand, an essential regulator of bone-removing cells (osteoclasts). Data were presented at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting in Houston, Sept. 12-15, 2014. In this exploratory analysis, results showed that Prolia enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic T-scores after eight years of treatment. By year eight, approximately 1,500 women remained in the open-label extension portion of the study.

Amgen Inc. Submits Marketing Authorization Application for Talimogene Laherparepvec to the European Medicines Agency

Amgen Inc. announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) through the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogene laherparepvec is an investigational oncolytic immunotherapy administered as an intralesional injection that is designed to initiate a systemic anti-tumor immune response. The MAA for talimogene laherparepvec contains data from more than 400 patients and is based on a global, randomized, open-label Phase 3 trial evaluating the safety and efficacy of talimogene laherparepvec in patients with stage IIIB, IIIC or IV melanoma when resection was not recommended compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). Melanoma is a type of skin cancer that is characterized by the uncontrolled growth of melanocytes, which are the cells responsible for providing the pigment to skin. Melanoma is the most aggressive and serious form of skin cancer. Currently, 132,000 melanoma cases occur globally each year. The number of people with melanoma is expected to rise considerably worldwide, with more than 279,000 projected new cases by the year 2020. Outcomes are substantially worse for people with regional and distantly metastatic disease, with high risk of recurrence for Stage IIIB, IIIC, and IV melanoma.

Amgen Inc. Plans to Lay Off over 12% of its Workforce

Amgen Inc. announced plans to lay off over 12% of the company's workforce, about 2,900 workers in all.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMGN:US $141.63 USD +0.92

AMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $146.92 USD +1.55
AbbVie Inc $59.36 USD -0.26
Gilead Sciences Inc $105.68 USD +1.84
Novo Nordisk A/S kr281.60 DKK +4.30
Teva Pharmaceutical Industries Ltd $52.46 USD +0.09
View Industry Companies
 

Industry Analysis

AMGN

Industry Average

Valuation AMGN Industry Range
Price/Earnings 21.3x
Price/Sales 5.4x
Price/Book 4.3x
Price/Cash Flow 21.1x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMGEN INC, please visit www.amgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.